(NASDAQ: FTRE) Fortrea Holdings's forecast annual revenue growth rate of 1.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.75%.
Fortrea Holdings's revenue in 2026 is $2,708,600,000.On average, 14 Wall Street analysts forecast FTRE's revenue for 2026 to be $251,541,400,000, with the lowest FTRE revenue forecast at $240,757,000,000, and the highest FTRE revenue forecast at $260,717,600,000. On average, 14 Wall Street analysts forecast FTRE's revenue for 2027 to be $259,487,800,000, with the lowest FTRE revenue forecast at $245,676,200,000, and the highest FTRE revenue forecast at $273,867,000,000.
In 2028, FTRE is forecast to generate $270,556,000,000 in revenue, with the lowest revenue forecast at $253,811,800,000 and the highest revenue forecast at $284,556,800,000.